{"protocolSection": {"identificationModule": {"nctId": "NCT02720081", "orgStudyIdInfo": {"id": "1029-015"}, "secondaryIdInfos": [{"id": "2015-005054-36", "type": "EUDRACT_NUMBER"}, {"id": "MK-1029-015", "type": "OTHER", "domain": "Merck Registration Number"}, {"id": "163313", "type": "REGISTRY", "domain": "JAPIC-CTI"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)", "officialTitle": "A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects With Persistent Asthma That is Uncontrolled While Receiving Montelukast."}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-05-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-08-16", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-09-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-03-22", "studyFirstSubmitQcDate": "2016-03-22", "studyFirstPostDateStruct": {"date": "2016-03-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-07-16", "resultsFirstSubmitQcDate": "2018-08-24", "resultsFirstPostDateStruct": {"date": "2018-08-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-30", "lastUpdatePostDateStruct": {"date": "2018-09-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this trial is to compare the safety, tolerability, and efficacy of adding MK-1029 to montelukast in adults with persistent asthma that is uncontrolled while receiving montelukast alone. Participants will have a specific genetic marker for clinical efficacy of MK-1029. The primary hypothesis is that when added to montelukast, treatment with MK-1029 is superior to placebo, as demonstrated by an increase in forced expiratory volume in one second (FEV1), measured as the average change from baseline at the end of Week 4 and Week 6 of treatment."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 142, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-1029 150 mg + Montelukast 10 mg", "type": "EXPERIMENTAL", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.", "interventionNames": ["Drug: MK-1029 150 mg", "Drug: Montelukast 10 mg", "Drug: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation"]}, {"label": "MK-1029 Placebo + Montelukast 10 mg", "type": "PLACEBO_COMPARATOR", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.", "interventionNames": ["Drug: MK-1029 Matching-image Placebo", "Drug: Montelukast 10 mg", "Drug: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation"]}], "interventions": [{"type": "DRUG", "name": "MK-1029 150 mg", "description": "150 mg tablet administered orally, once a day (QD), at bedtime", "armGroupLabels": ["MK-1029 150 mg + Montelukast 10 mg"]}, {"type": "DRUG", "name": "MK-1029 Matching-image Placebo", "description": "Matching-image placebo tablet administered orally, QD, at bedtime", "armGroupLabels": ["MK-1029 Placebo + Montelukast 10 mg"]}, {"type": "DRUG", "name": "Montelukast 10 mg", "description": "10 mg tablet administered orally, QD, at bedtime", "armGroupLabels": ["MK-1029 150 mg + Montelukast 10 mg", "MK-1029 Placebo + Montelukast 10 mg"], "otherNames": ["SINGULAIR\u00ae", "Montelukast sodium"]}, {"type": "DRUG", "name": "Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation", "description": "1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication", "armGroupLabels": ["MK-1029 150 mg + Montelukast 10 mg", "MK-1029 Placebo + Montelukast 10 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline Pre-dose Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second.", "timeFrame": "Before the first dose of study investigational product (Baseline)"}, {"measure": "Average Change From Baseline in Pre-dose FEV1 at Week 4 and Week 6", "description": "FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. Data presented represents the average change from baseline at Week 4 and Week 6.", "timeFrame": "Before the first dose (Baseline) and at the end of Weeks 4 and 6 of treatment"}], "secondaryOutcomes": [{"measure": "Percentage of Days With Worsening Asthma Average Over Weeks 3 to 6", "description": "A day with worsening asthma was defined as any day during which any of the following occurred: a decrease from baseline in morning (AM) peak expiratory flow (PEF) of more than 20%; AM PEF less than 180 liters/minute (L/min); an increase in \u03b2-agonist use of more than 70% (and a minimum increase of at least 2 puffs); an increase from baseline in daytime asthma symptom score of more than 50%; overnight asthma symptom of: Awake \"all night\"; an asthma attack, as defined by any day when one or more of the following events due to asthma has occurred: corticosteroid use (systemic); unscheduled visit to the doctor or urgent care clinic; unscheduled visit to the emergency department; and/or hospitalization. Participants needed at least 80% of days with a complete diary during Weeks 3 to 6. A diary is considered complete if none of the above 6 components used to determine asthma worsening are missing.", "timeFrame": "Up to 4 weeks"}, {"measure": "Percentage of Participants Who Experienced an Adverse Event (AE)", "description": "An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to 8 weeks"}, {"measure": "Percentage of Participants Who Discontinued Study Drug Due to an AE", "description": "An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to 6 weeks"}, {"measure": "Change From Baseline in Alkaline Phosphatase (ALP) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Alanine Aminotransferase (ALT) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Aspartate Aminotransferase (AST) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Bilirubin at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Eosinophil (Percent [%]) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Neutrophil (%) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Platelet Count at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in White Blood Cell Count at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Hematocrit (%) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Systolic Blood Pressure at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in Systolic Blood Pressure at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Systolic Blood Pressure at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Diastolic Blood Pressure at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in Diastolic Blood Pressure at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Diastolic Blood Pressure at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Heart Rate at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in Heart Rate at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Heart Rate at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline in Respiratory Rate at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in Respiratory Rate at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Respiratory Rate at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "timeFrame": "Baseline and Week 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Symptoms of persistent asthma for at least one year\n* History of asthma treatments including \"as-needed\" inhaled short-acting beta-agonists (albuterol/salbutamol); stable doses of inhaled corticosteroids (ICS), combination ICS/long-acting (inhaled) Beta2-adrenergic agonist (LABA) and/or oral asthma controller(s)\n* Must be able to discontinue or taper asthma controlling medications while receiving Montelukast\n* No history of smoking or no smoking for at least 1 year, with a smoking history of no more than 10 pack-years\n* Body Mass Index (BMI) of 15 kg/m\\^2 to 40 kg/m\\^2.\n* Females must not be pregnant (negative serum human chorionic gonadotropin test) or breastfeeding and must not plan to become pregnant for the duration of the study, including the post-treatment follow-up period\n* Women and male participants of reproductive potential must agree to use adequate contraception for the duration of the study\n\nExclusion Criteria:\n\n* Evidence of another active pulmonary disorder such as bronchiectasis or chronic obstructive pulmonary disease (COPD)\n* Unable to perform acceptable, repeatable spirometry\n* History of myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within 3 months of screening visit\n* Major surgical procedure(s) within 4 weeks of screening visit\n* Blood donation within 2 weeks of screening visit\n* Treatment in an emergency room for asthma (within 4 weeks) or hospitalization for asthma or respiratory condition within 2 months of screening visit\n* Evidence of active sinus disease within 2 weeks of screening visit\n* Upper respiratory infection (viral or bacterial) within 1 month of screening visit\n* History of a psychiatric disorder within 3 months of screening visit\n* History of human immunodeficiency virus (HIV)\n* Unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems\n* History of cancer (except for successfully treated basal and squamous cell carcinomas of the skin) within 5 years of screening visit\n* Uncontrolled hypertension\n* Participation in a clinical trial involving an investigational drug within 4 weeks of screening visit\n* Hypersensitivity or intolerance to inhaled beta-agonists and/or leukotriene inhibitors or any of their ingredients, including lactose and galactose\n* Known sensitivity to or has not had previous exposure to aspirin or non-steroidal anti-inflammatory drugs", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "FG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "72"}, {"groupId": "FG001", "numSubjects": "70"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "70"}, {"groupId": "FG001", "numSubjects": "69"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "66"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "BG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "44.4", "spread": "12.1"}, {"groupId": "BG001", "value": "42.2", "spread": "13.0"}, {"groupId": "BG002", "value": "43.3", "spread": "12.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "87"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "55"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "90"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "26"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "22"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Pre beta-agonist (\u03b2-agonist) forced expiratory volume in one second (FEV1) Predicted", "description": "If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population consists of participants with pre \u03b2-agonist FEV1 predicted baseline data.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liter (L)", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "70"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2.251", "spread": "0.572"}, {"groupId": "BG001", "value": "2.243", "spread": "0.631"}, {"groupId": "BG002", "value": "2.247", "spread": "0.600"}]}]}]}, {"title": "C Alleles at the pre-specified single nucleotide polymorphism (SNP)", "description": "Copies of C Alleles at the pre-specified SNP is the proposed genetic marker for response to MK-1029 for the treatment of asthma.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "1 copy", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "95"}]}]}, {"title": "2 copies", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "47"}]}]}]}, {"title": "Prior inhaled corticosteroid use", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Yes", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "54"}, {"groupId": "BG002", "value": "106"}]}]}, {"title": "No", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "142"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "36"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline Pre-dose Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second.", "populationDescription": "Analysis population consists of randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "Before the first dose of study investigational product (Baseline)", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.264", "spread": "0.566"}, {"groupId": "OG001", "value": "2.234", "spread": "0.612"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Days With Worsening Asthma Average Over Weeks 3 to 6", "description": "A day with worsening asthma was defined as any day during which any of the following occurred: a decrease from baseline in morning (AM) peak expiratory flow (PEF) of more than 20%; AM PEF less than 180 liters/minute (L/min); an increase in \u03b2-agonist use of more than 70% (and a minimum increase of at least 2 puffs); an increase from baseline in daytime asthma symptom score of more than 50%; overnight asthma symptom of: Awake \"all night\"; an asthma attack, as defined by any day when one or more of the following events due to asthma has occurred: corticosteroid use (systemic); unscheduled visit to the doctor or urgent care clinic; unscheduled visit to the emergency department; and/or hospitalization. Participants needed at least 80% of days with a complete diary during Weeks 3 to 6. A diary is considered complete if none of the above 6 components used to determine asthma worsening are missing.", "populationDescription": "Analysis population consists of randomized participants who received at least 1 dose of study drug and had at least 80% of days with a complete diary during Weeks 3 to 6 (a diary is considered complete if none of the 6 components used to determine asthma worsening are missing).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of days", "timeFrame": "Up to 4 weeks", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.970", "lowerLimit": "10.115", "upperLimit": "23.826"}, {"groupId": "OG001", "value": "21.746", "lowerLimit": "14.291", "upperLimit": "29.201"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.352", "statisticalMethod": "ANOVA", "statisticalComment": "Terms for treatment, number of C alleles at the pre-specified SNP, and prior inhaled corticosteroid use.", "paramType": "Difference in least squares means", "paramValue": "-4.775", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.92", "ciUpperLimit": "5.370"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Experienced an Adverse Event (AE)", "description": "An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "Analysis population included all randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 8 weeks", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.7"}, {"groupId": "OG001", "value": "26.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in percentages", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.0", "ciUpperLimit": "14.3", "estimateComment": "Based on Miettinen \\& Nurminen"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Discontinued Study Drug Due to an AE", "description": "An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "Analysis population included all randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 6 weeks", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "4.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in percentages", "paramValue": "-4.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.1", "ciUpperLimit": "1.0", "estimateComment": "Based on Miettinen \\& Nurminen"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Alkaline Phosphatase (ALP) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, ALP.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.16", "spread": "19.05"}, {"groupId": "OG001", "value": "67.96", "spread": "21.17"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "7.68"}, {"groupId": "OG001", "value": "0.44", "spread": "9.98"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Alanine Aminotransferase (ALT) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, ALT.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.33", "spread": "12.75"}, {"groupId": "OG001", "value": "19.35", "spread": "9.77"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.99", "spread": "9.84"}, {"groupId": "OG001", "value": "0.34", "spread": "6.31"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Aspartate Aminotransferase (AST) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, AST.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.53", "spread": "10.28"}, {"groupId": "OG001", "value": "20.64", "spread": "7.62"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "12.52"}, {"groupId": "OG001", "value": "0.76", "spread": "7.67"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Bilirubin at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, bilirubin.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.62", "spread": "0.25"}, {"groupId": "OG001", "value": "0.54", "spread": "0.21"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00", "spread": "0.25"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Eosinophil (Percent [%]) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, eosinophil (%).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent of White Blood Cells", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.40", "spread": "4.54"}, {"groupId": "OG001", "value": "3.58", "spread": "2.65"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "4.29"}, {"groupId": "OG001", "value": "0.51", "spread": "1.96"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Neutrophil (%) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, neutrophil (%).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent of White Blood Cells", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "59.13", "spread": "10.30"}, {"groupId": "OG001", "value": "57.86", "spread": "10.48"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.32", "spread": "10.53"}, {"groupId": "OG001", "value": "0.12", "spread": "9.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Platelet Count at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, platelet count.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "256.85", "spread": "60.83"}, {"groupId": "OG001", "value": "258.44", "spread": "70.23"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.97", "spread": "30.93"}, {"groupId": "OG001", "value": "2.65", "spread": "29.44"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in White Blood Cell Count at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, white blood cell count.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.76", "spread": "2.55"}, {"groupId": "OG001", "value": "6.53", "spread": "1.88"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "2.00"}, {"groupId": "OG001", "value": "0.09", "spread": "1.51"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Hematocrit (%) at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement is not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, hematocrit (%).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.79", "spread": "3.98"}, {"groupId": "OG001", "value": "42.64", "spread": "4.62"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "2.05"}, {"groupId": "OG001", "value": "-0.33", "spread": "1.86"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 2 for the analysis endpoint, systolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "118.89", "spread": "16.28"}, {"groupId": "OG001", "value": "118.83", "spread": "15.64"}]}]}, {"title": "Change at Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.61", "spread": "9.00"}, {"groupId": "OG001", "value": "-1.23", "spread": "10.79"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 4 for the analysis endpoint, systolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "119.40", "spread": "16.22"}, {"groupId": "OG001", "value": "118.82", "spread": "15.88"}]}]}, {"title": "Change at Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.13", "spread": "10.14"}, {"groupId": "OG001", "value": "-1.99", "spread": "11.45"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, systolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "119.40", "spread": "16.22"}, {"groupId": "OG001", "value": "118.77", "spread": "16.00"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.34", "spread": "9.36"}, {"groupId": "OG001", "value": "-2.26", "spread": "11.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 2 for the analysis endpoint, diastolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.40", "spread": "10.79"}, {"groupId": "OG001", "value": "74.45", "spread": "10.49"}]}]}, {"title": "Change at Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.31", "spread": "7.67"}, {"groupId": "OG001", "value": "-0.97", "spread": "6.88"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 4 for the analysis endpoint, diastolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.60", "spread": "10.88"}, {"groupId": "OG001", "value": "74.42", "spread": "10.49"}]}]}, {"title": "Change at Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.56", "spread": "7.71"}, {"groupId": "OG001", "value": "-1.60", "spread": "8.01"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, diastolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.60", "spread": "10.88"}, {"groupId": "OG001", "value": "74.29", "spread": "10.51"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.18", "spread": "8.30"}, {"groupId": "OG001", "value": "-0.95", "spread": "7.71"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Heart Rate at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 2 for the analysis endpoint, heart rate.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.21", "spread": "10.96"}, {"groupId": "OG001", "value": "74.20", "spread": "10.03"}]}]}, {"title": "Change at Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "spread": "7.84"}, {"groupId": "OG001", "value": "0.45", "spread": "9.38"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Heart Rate at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 4 for the analysis endpoint, heart rate.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.25", "spread": "11.12"}, {"groupId": "OG001", "value": "73.96", "spread": "10.01"}]}]}, {"title": "Change at Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.82", "spread": "9.18"}, {"groupId": "OG001", "value": "1.40", "spread": "9.38"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Heart Rate at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, heart rate.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.25", "spread": "11.12"}, {"groupId": "OG001", "value": "73.80", "spread": "10.01"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "spread": "8.82"}, {"groupId": "OG001", "value": "1.06", "spread": "10.10"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Respiratory Rate at Week 2", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 2 for the analysis endpoint, respiratory rate.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "breaths/min", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.40", "spread": "2.61"}, {"groupId": "OG001", "value": "17.23", "spread": "3.78"}]}]}, {"title": "Change at Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "1.93"}, {"groupId": "OG001", "value": "-1.17", "spread": "3.64"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Respiratory Rate at Week 4", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 4 for the analysis endpoint, respiratory rate.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "breaths/min", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.43", "spread": "2.60"}, {"groupId": "OG001", "value": "17.18", "spread": "3.82"}]}]}, {"title": "Change at Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12", "spread": "2.58"}, {"groupId": "OG001", "value": "-0.97", "spread": "3.24"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Respiratory Rate at Week 6", "description": "Baseline was defined at Week 0. If Week 0 measurement was not available, the last non-missing value before treatment was used as Baseline.", "populationDescription": "Analysis population includes all participants who received at least 1 dose of study drug and had non-missing change from baseline value at Week 6 for the analysis endpoint, respiratory rate.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "breaths/min", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.43", "spread": "2.60"}, {"groupId": "OG001", "value": "17.20", "spread": "3.84"}]}]}, {"title": "Change at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "2.30"}, {"groupId": "OG001", "value": "-1.17", "spread": "3.20"}]}]}]}, {"type": "PRIMARY", "title": "Average Change From Baseline in Pre-dose FEV1 at Week 4 and Week 6", "description": "FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. Data presented represents the average change from baseline at Week 4 and Week 6.", "populationDescription": "Analysis population consists of randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liter", "timeFrame": "Before the first dose (Baseline) and at the end of Weeks 4 and 6 of treatment", "groups": [{"id": "OG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}, {"id": "OG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.152", "lowerLimit": "0.088", "upperLimit": "0.217"}, {"groupId": "OG001", "value": "0.046", "lowerLimit": "-0.020", "upperLimit": "0.111"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.023", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Terms for treatment, time, interaction of time by treatment, number of C alleles at the pre-specified SNP, and prior inhaled corticosteroid use.", "paramType": "Difference in least squares means", "paramValue": "0.107", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.015", "ciUpperLimit": "0.199"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 8 weeks", "description": "Analysis population included all randomized participants who received at least 1 dose of study drug.", "eventGroups": [{"id": "EG000", "title": "MK-1029 150 mg + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.", "deathsNumAffected": 0, "deathsNumAtRisk": 70, "seriousNumAffected": 0, "seriousNumAtRisk": 70, "otherNumAffected": 6, "otherNumAtRisk": 70}, {"id": "EG001", "title": "MK-1029 Placebo + Montelukast 10 mg", "description": "Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.", "deathsNumAffected": 0, "deathsNumAtRisk": 69, "seriousNumAffected": 1, "seriousNumAtRisk": 69, "otherNumAffected": 9, "otherNumAtRisk": 69}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 70}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 69}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 70}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 69}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-03-03", "uploadDate": "2018-07-16T14:40", "filename": "Prot_SAP_000.pdf", "size": 2567095}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Guatemala", "Japan", "Malaysia", "Poland", "South Africa"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}